5,5'-(1H-isoindole-1,3(2H)-diylidene)dibarbituric acid

Acute Toxicity: other routes

Administrative data

Endpoint:

acute toxicity: other routes

Type of information:

experimental study

Adequacy of study:

supporting study

Reliability:

2 (reliable with restrictions)

Rationale for reliability incl. deficiencies:

other: Meets generally accepted scientific standards (without detailed documentation)

Data source

Reference

Reference 1

Reference Type:

study report

Title:

Unnamed

Year:

1973

Report date:

1973

Reference 2

Reference Type:

other company data

Title:

Unnamed

Year:

2002

Report date:

2002

Materials and methods

Principles of method if other than guideline:

5 mice per sex per dose were administered a single dose of the test substance via intraperitoneal injection. Clinical signs were monitored and necropsy was carried out at termination or after death if an animal died during the study. Observation period was until day 7.

GLP compliance:

no

Limit test:

no

Test material

Test material information

Constituent 1

Reference substance name:

5,5'-(1H-isoindole-1,3(2H)-diylidene)dibarbituric acid

EC Number:

253-256-2

EC Name:

5,5'-(1H-isoindole-1,3(2H)-diylidene)dibarbituric acid

Cas Number:

36888-99-0

Molecular formula:

C16H9N5O6

IUPAC Name:

5,5'-(1H-isoindole-1,3(2H)-diylidene)dipyrimidine-2,4,6(1H,3H,5H)-trione

Test material form:

solid

Details on test material:

- Physical state: solid
- Analytical purity: no data

Test animals

Species:

mouse

Strain:

not specified

Sex:

male/female

Details on test animals or test system and environmental conditions:

TEST ANIMALS
- Source: Kisslegg
- Weight at study initiation (mean values): 31.0 g (males), 26.1 g (females)

ENVIRONMENTAL CONDITIONS: not reported

Administration / exposure

Route of administration:

intraperitoneal

Vehicle:

CMC (carboxymethyl cellulose)

Remarks:

(aqueous solution)

Doses:

3200 and 6400 mg/kg bw (30% in CMC solution)

No. of animals per sex per dose:

5

Control animals:

no

Details on study design:

- Duration of observation period following administration: 7 days
- Frequency of observations (after application): 2 h and 1, 4, 5 and 6 days
- Frequency of weighing: only before application
- Necropsy of survivors performed: yes
- Other examinations performed: clinical signs

Statistics:

not performed

Results and discussion

Effect levels

Sex:

male/female

Dose descriptor:

LD50

Effect level:

> 6 400 mg/kg bw

Based on:

test mat.

Mortality:

No mortality was observed.

Clinical signs:

After application: accelerated respiration, spastic gait and streching
Between 2 h and 4 days after application: hunched body posture, closed eyes and accelerated respiration

Body weight:

no data

Gross pathology:

Orange coloured substance residues in the abdomen in both dose groups.